TL;DR
This study reveals that endothelial cells, under pathological low shear stress, release Dickkopf-1 (DKK1) which is then taken up by smooth muscle cells (SMCs). This DKK1 promotes SMCs to become foam cells by stabilizing the scavenger receptor SR-A through USP53-mediated deubiquitination, ultimately contributing to atherosclerosis development. Targeting endothelial DKK1 could be a new therapeutic strategy for this disease.
What Problem Does This Paper Address?
Atherosclerosis (AS) is a chronic inflammatory disease characterized by the buildup of lipid-rich plaques in arteries. A key event in AS is the formation of foam cells, which are lipid-laden cells that contribute to plaque progression. While macrophages have long been considered the primary foam cell precursors, recent research highlights the significant contribution of smooth muscle cells (SMCs) to foam cell populations within atherosclerotic plaques. Endothelial cells (ECs), lining the blood vessels, are directly exposed to mechanical forces like shear stress, which can lead to dysfunction and contribute to AS. Specifically, low shear stress, often found at arterial bifurcations, is known to induce EC dysfunction and promote AS. Dickkopf-1 (DKK1) is a protein secreted by ECs that is known to be upregulated under pathological shear stress and plays a role in EC dysfunction. However, the paracrine (cell-to-cell signaling) role of EC-secreted DKK1 in modulating the behavior of adjacent SMCs, particularly in the context of foam cell formation under shear stress, remained largely unexplored. This paper aims to elucidate this crucial intercellular communication pathway and its implications for atherosclerosis.
Methods
The researchers employed a multi-pronged approach combining in vitro and in vivo models:
- In Vitro Co-culture System: A parallel-plate co-culture flow system was used to mimic the in vivo environment, allowing for the study of interactions between ECs and SMCs under controlled shear stress conditions (normal shear stress vs. low shear stress). This system enabled the investigation of cellular communication and the effects of EC-secreted factors on SMCs.
- Genetic Manipulation:
- Endothelium-specific DKK1 knockout (DKK1<sup>ECKO</sup>/APOE<sup>-/-</sup>) mice: These mice were engineered to specifically lack DKK1 in their endothelial cells, while also having a predisposition to atherosclerosis (due to APOE deficiency). This allowed researchers to study the consequences of removing endothelial DKK1 on AS development.
- Endothelium-specific DKK1 overexpression (DKK1<sup>ECTg</sup>) mice: Conversely, these mice were engineered to overexpress DKK1 specifically in their endothelial cells, enabling the study of the effects of increased endothelial DKK1.
- siRNA-mediated knockdown: DKK1 and USP53 were knocked down in ECs and SMCs, respectively, using small interfering RNA (siRNA) to investigate their specific roles.
- Adeno-associated virus (AAV) vectors: AAV vectors were used to overexpress USP53 specifically in SMCs in vivo to rescue the effects of DKK1 deficiency.
- Molecular Biology Techniques:
- RNA sequencing (RNA-seq): Used to identify downstream targets of DKK1 in SMCs.
- RT-qPCR: To quantify mRNA levels of specific genes.
- Western Blot: To measure protein expression levels.
- Co-immunoprecipitation (Co-IP): To confirm protein-protein interactions (e.g., USP53 and SR-A).
- Chromatin Immunoprecipitation (ChIP): To investigate the binding of transcription factors (like CREB) to gene promoters.
- Histological and Imaging Techniques:
- Immunofluorescence staining: To visualize the localization of proteins and cells within tissues and cell cultures.
- Oil Red O, BODIPY493/503, and DIL-oxLDL staining: To assess lipid accumulation and uptake in SMCs.
- Masson staining: To evaluate collagen content in atherosclerotic plaques.
- Pharmacological Inhibition: Inhibitors for proteasomes, lysosomes, and autophagy were used to determine the protein degradation pathways involved.
Datasets
Not explicitly discussed as distinct datasets for training or evaluation in the context of machine learning. The study utilizes data generated from:
- In vitro experiments: Cell cultures (HAECs, HASMCs, HEK293T) treated under various conditions.
- In vivo experiments: Mouse models (DKK1<sup>ECKO</sup>/APOE<sup>-/-</sup>, DKK1<sup>ECTg</sup>, WT mice) with induced atherosclerosis.
- Human samples: Carotid plaque biopsies were used for histological analysis.
- RNA sequencing data: Generated from SMCs treated with rDKK1 or DKK1 siRNA. This data has been submitted to the GEO repository (PRJNA851945).
Key Insights and Ideas
- Low Shear Stress as a DKK1 Trigger: Pathological low shear stress, a common condition in atherosclerotic-prone regions, directly upregulates DKK1 expression in endothelial cells. This highlights a specific environmental cue that initiates the cascade.
- Paracrine Signaling from ECs to SMCs: The study firmly establishes that EC-secreted DKK1 acts as a paracrine signal, influencing the behavior of adjacent SMCs. This moves beyond the understanding of DKK1's autocrine effects on ECs.
- SMCs as Key Targets: DKK1 receptors (CKAP4 and LRP6) are highly expressed on SMCs, making them primary functional targets for EC-derived DKK1. This explains why SMCs are so responsive to this signal.
- DKK1's Role in Foam Cell Formation: DKK1 directly promotes lipid uptake and foam cell formation in SMCs, a critical step in atherosclerosis. This is a novel finding linking DKK1 to SMC-specific foam cell genesis.
- USP53 as a Crucial Mediator: The study identifies Ubiquitin-specific Protease 53 (USP53) as a key downstream target of DKK1 in SMCs. USP53's role in deubiquitinating and stabilizing SR-A is a central mechanistic insight.
- Deubiquitination of SR-A: The discovery that USP53 deubiquitinates SR-A, specifically removing K48-linked ubiquitin chains, thereby preventing proteasomal degradation, is a significant molecular mechanism. This explains how DKK1 leads to increased SR-A protein levels.
- CREB as a Transcriptional Regulator of USP53: The finding that DKK1 upregulates USP53 transcription by facilitating CREB binding to the USP53 promoter provides a hierarchical understanding of the signaling pathway.
- Targeted Intervention Potential: The successful reversal of atherosclerotic phenotypes by overexpressing USP53 in DKK1-deficient mice strongly suggests that the DKK1-USP53-SR-A axis is a viable therapeutic target.
Key Results
- DKK1 Upregulation: Low shear stress significantly increased DKK1 mRNA and protein in ECs. While DKK1 protein also increased in co-cultured SMCs, their mRNA levels remained unchanged, indicating uptake of EC-derived DKK1.
- SR-A Upregulation and Foam Cell Formation: DKK1 promoted lipid deposition, lipid uptake, and SR-A expression in SMCs. Knockdown of DKK1 in ECs or blocking DKK1 with an antibody reversed these effects.
- USP53 Dependence: DKK1-induced SR-A upregulation in SMCs was dependent on USP53. Knockdown of USP53 attenuated DKK1's effects on SR-A expression, lipid accumulation, and foam cell formation.
- USP53 Mechanism: USP53 directly interacts with SR-A and deubiquitinates it, specifically removing K48-linked ubiquitin chains, thereby stabilizing SR-A protein and preventing its proteasomal degradation.
- CREB Regulation: DKK1 treatment upregulated CREB, which in turn bound to the USP53 promoter, leading to increased USP53 transcription.
- In Vivo Validation:
- Endothelial-specific DKK1 knockout mice (DKK1<sup>ECKO</sup>/APOE<sup>-/-</sup>) showed reduced atherosclerotic plaque burden, lipid accumulation, and SR-A expression in SMCs within plaques.
- Endothelial-specific DKK1 overexpression mice (DKK1<sup>ECTg</sup>) exhibited exacerbated atherosclerosis and increased lipid accumulation in SMCs.
- SMC-specific USP53 overexpression in DKK1<sup>ECKO</sup>/APOE<sup>-/-</sup> mice reversed the protective effects of DKK1 deficiency, restoring plaque burden and lipid accumulation.
Limitations and Future Work
- DKK1 Uptake Mechanism: The study acknowledges that further investigation is needed to fully elucidate the pathway of endothelial DKK1 uptake by SMCs.
- Therapeutic Efficacy of DKK1 Neutralizing Antibody: While the study used a neutralizing antibody in vitro and showed in vivo benefits of DKK1 knockout, the therapeutic efficacy of a DKK1 neutralizing antibody in murine AS models needs to be further determined.
- SMC Lineage Tracing: The authors suggest that SMC lineage tracing would be the most direct approach to validate their findings on foam cell formation in SMCs.
- Broader Therapeutic Implications: The study notes that while targeting endothelial DKK1 can inhibit its autocrine effects on ECs, its paracrine effects on SMCs are only partially alleviated. This suggests that a comprehensive therapeutic strategy might need to consider both aspects.
- "Killing Two Birds with One Stone": The authors propose that DKK1, being a target for cancer therapy, could potentially be targeted for AS as well, suggesting a dual therapeutic benefit. Future work could explore this combined therapeutic approach.
Summary updated